文献速递精神分裂症与精神病性障碍

抗精神病药与认知行为治疗及两者联合治疗精神病性障碍的随机对照预试验

Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study.
PubMed 文献 · Lancet Psychiatry · 2018-04-05

该单中心、单盲预试验将75名精神病性障碍患者随机分为CBT组、抗精神病药组及联合组,评估可行性。头对头比较可行且安全。

要点

  • 联合治疗较单用CBT显著改善PANSS总分,但与单用抗精神病药无显著差异。
  • CBT组非神经性副作用显著少于抗精神病药组和联合组。
  • 在精神病性障碍中开展CBT与抗精神病药头对头试验可行且安全。

核心结论

  • 在精神病性障碍患者中开展CBT、抗精神病药及两者联合的头对头随机对照试验是可行且安全的。
  • 联合组PANSS总分较CBT组显著降低,但与抗精神病药组无显著差异;CBT组副作用显著少于两药物组。

研究设计与样本

  • 单中心、单盲预试验随机对照试验,在英国大曼彻斯特NHS信托机构招募75名精神病性障碍患者,按1:1:1随机分为CBT组(26例)、抗精神病药组(24例)和联合组(25例)。
  • CBT最多26次治疗(6个月内)加最多4次强化治疗;抗精神病药选择和剂量由治疗顾问决定;随访1年。
  • 主要可行性指标为招募、保留和可接受性;主要疗效指标为PANSS总分(基线、6、12、24、52周评估)。
  • 非神经性副作用用抗精神病药非神经性副作用评定量表系统评估;主要分析按意向治疗,安全性分析按实际治疗。

主要发现

  • 仅1例严重不良事件被认为与试验相关(CBT组过量服用3片对乙酰氨基酚)。

关键数值与推荐

  • 纳入标准:年龄≥16岁;符合ICD-10精神分裂症、分裂情感性障碍或妄想障碍诊断,或符合早期精神病干预服务准入标准;PANSS妄想或幻觉条目≥4分,或猜疑、被害、夸大条目≥5分;有知情同意能力且主动求助。

临床怎么用

  • 结果支持在精神病性障碍(包括首发精神病)中开展CBT与抗精神病药头对头比较的可行性。
  • CBT可作为副作用较少的治疗选择,联合治疗可能较单用CBT改善总体症状,但需更大样本验证。

局限性

  • 预试验样本量小(75例),主要目的为可行性,疗效比较证据有限。
  • 单中心、单盲设计,抗精神病药选择和剂量由临床医生决定,可能引入异质性。
  • 22%随机分配至抗精神病药组的患者未处方规律抗精神病药,可能影响治疗依从性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little evidence is available for head-to-head comparisons of psychosocial interventions and pharmacological interventions in psychosis. We aimed to establish whether a randomised controlled trial of cognitive behavioural therapy (CBT) versus antipsychotic drugs versus a combination of both would be feasible in people with psychosis. METHODS: We did a single-site, single-blind pilot randomised controlled trial in people with psychosis who used services in National Health Service trusts across Greater Manchester, UK. Eligible participants were aged 16 years or older; met ICD-10 criteria for schizophrenia, schizoaffective disorder, or delusional disorder, or met the entry criteria for an early intervention for psychosis service; were in contact with mental health services, under the care of a consultant psychiatrist; scored at least 4 on delusions or hallucinations items, or at least 5 on suspiciousness, persecution, or grandiosity items on the Positive and Negative Syndrome Scale (PANSS); had capacity to consent; and were help-seeking. Participants were assigned (1:1:1) to antipsychotics, CBT, or antipsychotics plus CBT. Randomisation was done via a secure web-based randomisation system (Sealed Envelope), with randomised permuted blocks of 4 and 6, stratified by gender and first episode status. CBT incorporated up to 26 sessions over 6 months plus up to four booster sessions. Choice and dose of antipsychotic were at the discretion of the treating consultant. Participants were followed up for 1 year. The primary outcome was feasibility (ie, data about recruitment, retention, and acceptability), and the primary efficacy outcome was the PANSS total score (assessed at baseline, 6, 12, 24, and 52 weeks). Non-neurological side-effects were assessed systemically with the Antipsychotic Non-neurological Side Effects Rating Scale. Primary analyses were done by intention to treat; safety analyses were done on an as-treated basis. The study was prospectively registered with ISRCTN, number ISRCTN06022197. FINDINGS: Of 138 patients referred to the study, 75 were recruited and randomly assigned-26 to CBT, 24 to antipsychotics, and 25 to antipsychotics plus CBT. Attrition was low, and retention high, with only four withdrawals across all groups. 40 (78%) of 51 participants allocated to CBT attended six or more sessions. Of the 49 participants randomised to antipsychotics, 11 (22%) were not prescribed a regular antipsychotic. Median duration of total antipsychotic treatment was 44·5 weeks (IQR 26-51). PANSS total score was significantly reduced in the combined intervention group compared with the CBT group (-5·65 [95% CI -10·37 to -0·93]; p=0·019). PANSS total scores did not differ significantly between the combined group and the antipsychotics group (-4·52 [95% CI -9·30 to 0·26]; p=0·064) or between the antipsychotics and CBT groups (-1·13 [95% CI -5·81 to 3·55]; p=0·637). Significantly fewer side-effects, as measured with the Antipsychotic Non-neurological Side Effects Rating Scale, were noted in the CBT group than in the antipsychotics (3·22 [95% CI 0·58 to 5·87]; p=0·017) or antipsychotics plus CBT (3·99 [95% CI 1·36 to 6·64]; p=0·003) groups. Only one serious adverse event was thought to be related to the trial (an overdose of three paracetamol tablets in the CBT group). INTERPRETATION: A head-to-head clinical trial of CBT versus antipsychotics versus the combination of the two is feasible and safe in people with first-episode psychosis. FUNDING: National Institute for Health Research.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Morrison AP, Law H, Carter L, et al. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. Lancet Psychiatry. 2018. PMID: 29605187. doi:10.1016/S2215-0366(18)30096-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。